Reprint

Immunotherapy, Tumor Microenvironment and Survival Signaling

Edited by
June 2022
376 pages
  • ISBN978-3-0365-4419-9 (Hardback)
  • ISBN978-3-0365-4420-5 (PDF)

This book is a reprint of the Special Issue Immunotherapy, Tumor Microenvironment and Survival Signaling that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.  

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
Autophagy; colorectal cancer; immunotherapy; tumor stroma; tumor microenvironment; immune checkpoint inhibitors; chemotherapy; tyrosine kinase inhibitors; angiogenesis; check point inhibitors; programmed cell death protein 1; programmed cell death 1 ligand 1; cardiotoxicity; lung metastasis; CAR-T; hypoxia; tumor; microenvironment; CD19; BCMA; immunotherapy; cancer; melanoma; immune escape; antigen loss; immunotherapy; chimeric antigen receptor; electroporation; lentivirus; lentiviral transduction; tumor microenvironment; macrophages; leukemia cells; lytic peptides; targeted therapy; immunotherapy; cancer; colorectal cancer; dendritic cells; immunotherapy; pathogenesis; risk factors; immunotherapy; breast cancer; resistance; checkpoint; targeted treatment; personalized medicine; pediatric solid tumors; immunotherapy; chimeric antigen receptors; cancer vaccines; oncolytic viral therapy; immune checkpoint inhibitors; immunomodulation; DCLK1; CAR-T; tumor stem cells; immunotherapy; clonogenicity; cancer; mitochondria; mitochondrial transfer; tunneling nanotubes; tumor microenvironment; triple-negative breast cancer; immunotherapy; immune checkpoint inhibitor; combination therapy; tumor microenvironment; cancer nanomedicine; tumor antigens; chimeric antigen receptor; cancer metabolism; cancer; cancer immunotherapy; nanoparticles; immunotherapeutic agent; immunomodulators; DCLK1; tuft cells; cancer stem cells; microenvironment; immunotherapies; myeloid-derived suppressor cells; regulatory T cells; crosstalk; tumor microenvironment; tumor immune evasion; immunotherapy; cell–cell contact; β2 integrins; CD18; CD11; chimeric antigen receptor; CAR-T cells; CD37; CD19; immunotherapy; cell therapy; tumor antigen; lymphoma; CAR macrophage; CAR T cell; immunotherapy; solid tumors; immunometabolism; tumor microenvironment; miRNA; immunogenic cell death; cancer; n/a